CCM
LXRX icon

Cupps Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cupps Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.13M Buy
+62,549
New +$1.01M 0.49% 84

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cupps Capital Management's LXRX Position: Q3 2016 in Review

Cupps Capital Management opened a new position in Lexicon Pharmaceuticals (LXRX) in Q3 2016: 62,549 shares worth $1.13M. The stake represents 0.49% of the portfolio and ranks #84 among its holdings.

144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • Cupps Capital Management held 62,549 shares of Lexicon Pharmaceuticals worth $1.13M as of Q3 2016.
  • Lexicon Pharmaceuticals was a new Cupps Capital Management position in Q3 2016.
  • Lexicon Pharmaceuticals made up 0.49% of Cupps Capital Management's portfolio in Q3 2016, its #84 holding.
  • 144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.